Our Exosome for RNA Delivery services help biotechnology companies, pharmaceutical research teams, academic laboratories, and delivery-platform developers evaluate extracellular vesicles as carriers for functional RNA cargo. The platform supports siRNA, miRNA, mRNA, circular RNA, antisense oligonucleotides, and guide RNA programs requiring coordinated vesicle sourcing, RNA loading, purification, characterization, uptake analysis, and functional validation.
Exosome-mediated RNA delivery is not a single standardized formulation process. Vesicle source, RNA size and chemistry, loading route, free-RNA removal, particle integrity, cellular uptake, and cytosolic cargo release can all influence experimental outcomes. Our workflow connects RNA design with exosome engineering and application-specific testing, helping teams build interpretable research systems rather than relying only on apparent loading or fluorescence-based uptake.
Figure 1. Exosomes are rich in tetraspanins, adhesion molecules, enzymes, scaffolds, RNA-binding proteins, RNAs, DNAs, and complex glycans. (D, M. Pegtel.; et al, 2019)
Protecting RNA Without Compromising Function: Encapsulation can reduce RNA exposure to extracellular nucleases, but unsuitable loading conditions may damage long RNA, alter secondary structure, or reduce vesicle integrity. We match loading conditions to RNA length, modification pattern, concentration, and functional readout so that cargo protection is evaluated together with biological activity.
Separating True Loading From Free RNA: Fluorescent signal or total RNA recovery alone cannot confirm that RNA is located inside vesicles. Unbound RNA, membrane-associated material, and RNA aggregates may inflate apparent loading results. Our workflows incorporate post-loading purification, cargo-only controls, and nuclease-protection testing with and without membrane disruption to distinguish protected cargo from externally associated RNA.
Managing Vesicle Source Variability: Exosome and small extracellular vesicle preparations differ according to donor cell, culture conditions, collection schedule, isolation method, and background components. These variables can affect particle yield, endogenous RNA content, surface composition, and recipient-cell interactions. We establish source-selection criteria and matched unloaded-vesicle controls before loading studies begin.
Distinguishing Uptake From Functional Delivery: Cell-associated fluorescence may indicate membrane binding, internalization, dye transfer, or endosomal accumulation rather than release of functional RNA into the intended intracellular compartment. Our validation plans combine uptake measurements with cargo-specific readouts such as target knockdown, reporter expression, RNA recovery, or pathway-responsive assays.
Building Reproducible Preparations: Changes in particle concentration, RNA-to-vesicle ratio, buffer composition, purification recovery, storage time, and freeze-thaw history can create batch-to-batch variation. We define measurable process parameters and fit-for-purpose acceptance criteria so that exploratory formulations can be compared across experiments and transferred into larger research studies.
Our service platform covers the key decisions required to develop an RNA-loaded exosome or small extracellular vesicle system. Projects may begin with client-supplied RNA and vesicles or with a broader program that includes RNA preparation, donor-cell selection, vesicle production, loading optimization, purification, analytical testing, and cell-based evaluation.
Each program is structured around a defined research question. Rather than applying one loading method to every cargo, we assess RNA properties, required dose range, target-cell model, measurement strategy, and material constraints before selecting the experimental design.
RNA cargoes differ substantially in length, structure, susceptibility to degradation, and required intracellular destination. The matrix below summarizes practical factors used to select an initial exosome loading and validation strategy. Final conditions should be determined experimentally because loading performance depends on the complete combination of cargo, vesicle source, buffer, purification method, and analytical workflow.
| RNA Cargo | Primary Research Objective | Loading Options | Key Development Risks | Recommended Readouts |
| siRNA | Sequence-specific target knockdown in recipient cells | Electroporation, sonication, transfection-assisted loading, donor-cell loading, or engineered RNA-sorting systems | RNA aggregation, low protected loading, duplex damage, endosomal retention, and misleading fluorescence signals | Nuclease protection, intact-duplex analysis, target mRNA measurement, protein-level confirmation, and dose-response testing |
| miRNA | Modulation of miRNA-responsive pathways or evaluation of miRNA transport | Donor-cell expression, transfection-assisted loading, electroporation, or membrane-permeabilization methods | Endogenous miRNA background, sequence-family cross-reactivity, variable copy number, and incomplete functional release | Cargo-specific RT-qPCR or digital PCR, reporter assay, target-panel analysis, and unloaded-vesicle controls |
| mRNA | Transient expression of a reporter or research protein | Donor-cell expression, active sorting systems, cellular loading approaches, or optimized post-isolation loading | Large cargo size, RNA fragmentation, low loading, residual free mRNA, and loss of translation competence | RNA integrity, protected copy number, reporter-protein expression, time-course analysis, and translation-dependent controls |
| circRNA | Evaluation of circular RNA stability, translation, or regulatory activity | Donor-cell production, transfection-assisted loading, or cargo-specific active-loading development | Purity of circularized RNA, linear RNA contamination, size-dependent loading limitations, and assay-specific background | Circularity verification, protected cargo analysis, linear RNA assessment, and functional expression testing |
| Guide RNA | Delivery of guide RNA alone or as part of a genome-editing research system | Donor-cell loading, engineered sorting, post-isolation loading, or coordinated delivery with protein or mRNA components | Guide degradation, stoichiometric mismatch, incomplete co-delivery, and insufficient intracellular availability | Guide integrity, co-cargo analysis, reporter editing assay, sequence-level outcome analysis, and component-specific controls |
| Antisense Oligonucleotide | Steric blocking, transcript modulation, or splice-related research | Incubation for selected chemistries, electroporation, sonication, membrane permeabilization, or surface association | External adsorption mistaken for encapsulation, chemistry-dependent membrane interaction, and intracellular release limitations | Nuclease protection, membrane-disruption control, target RNA analysis, and sequence-matched negative controls |
Reliable exosome RNA delivery studies require complementary measurements of vesicle properties, cargo association, purity, and biological function. No single marker or particle-counting method is sufficient to establish preparation identity or delivery performance. Characterization plans should reflect the source material, separation process, loading method, and intended experimental conclusion.
| Evaluation Category | Purpose | Typical Methods | Key Interpretation Point | Project Stage |
| Particle Concentration and Size | Measure particle recovery and identify distribution changes after loading or storage | Nanoparticle tracking analysis, tunable resistive pulse sensing, dynamic light scattering, or complementary approaches | Particle counts should be interpreted with method detection limits and non-vesicular particle background in mind | Source Qualification / Loading / Stability |
| Vesicle Morphology | Examine particle structure and detect gross damage or aggregation | Transmission electron microscopy, cryogenic electron microscopy, or atomic force microscopy | Sample preparation can affect apparent morphology, so imaging should support rather than replace other measurements | Source Qualification / Process Comparison |
| Protein Marker Profile | Characterize vesicle-associated proteins and evaluate cellular contamination | Western blotting, bead-based flow analysis, ELISA, or targeted protein assays | Marker panels should include relevant vesicle-associated proteins and source-appropriate negative controls | Source Qualification / Batch Review |
| Free RNA Removal | Separate loaded vesicles from unbound RNA, aggregates, and loading reagents | Size-exclusion chromatography, ultrafiltration, density-based separation, or combined purification | Recovery and purity must be assessed together because aggressive cleanup may reduce usable vesicle yield | Post-Loading |
| Cargo Encapsulation | Distinguish protected RNA from surface-bound or freely dispersed material | Nuclease treatment with and without detergent, fluorescence assays, RT-qPCR, digital PCR, or sequence-specific analysis | A matched cargo-only control is needed to identify RNA precipitation or assay background | Loading Optimization / Release Testing |
| RNA Integrity | Confirm that loading and storage have not damaged the RNA cargo | Capillary electrophoresis, gel analysis, chromatography, sequencing, or cargo-specific structural assays | Total recovered RNA does not demonstrate that the cargo remains full length or functionally competent | Input Qualification / Post-Loading / Stability |
| Cellular Uptake | Measure vesicle association and internalization in the selected cell model | Flow cytometry, microscopy, imaging flow cytometry, or quantitative cellular RNA analysis | Dye transfer, surface binding, and endosomal accumulation should be controlled before uptake is interpreted as cargo delivery | Feasibility / Candidate Comparison |
| Functional Delivery | Demonstrate that RNA reaches a compartment where it can produce the intended molecular effect | Target knockdown, reporter expression, pathway-responsive assays, protein measurement, or sequence-level analysis | Functional endpoints should be linked to RNA dose and compared with free-RNA, unloaded-vesicle, and benchmark-carrier controls | Candidate Selection / Research Validation |
| Formulation Stability | Determine whether particle and cargo properties are maintained during storage and handling | Time-point testing of particle size, concentration, RNA retention, morphology, and functional activity | Physical stability and biological activity may decline differently and should be monitored independently | Method Transfer / Expanded Studies |
The workflow is adapted to the RNA cargo, available starting materials, and intended research model. Defined controls and decision criteria are established early so that each stage generates information needed for method selection and candidate progression.
We confirm the RNA type, sequence, modification pattern, available quantity, vesicle source, target-cell model, intended readout, and required deliverables. Existing data and client-supplied protocols are reviewed to identify material limitations and unresolved technical questions.
A project plan is prepared covering vesicle sourcing, loading routes, purification, analytical testing, dose definition, and functional controls. Alternative loading methods may be included when cargo properties or prior results do not support a single clear approach.
RNA and vesicle inputs are prepared or qualified for the planned study. Vesicles may be isolated and concentrated from selected donor-cell material, while RNA quality, concentration, integrity, and labeling status are checked before loading.
Candidate loading conditions are executed using defined RNA-to-vesicle ratios and process settings. Loaded preparations are purified to remove free cargo, aggregates, and process reagents, with particle and RNA recovery tracked across the workflow.
Vesicle properties, protected RNA, cargo integrity, cellular uptake, and functional delivery are evaluated using the agreed analytical package. Candidate formulations are compared with unloaded-vesicle, free-RNA, cargo-only process, and benchmark-delivery controls.
Results are reviewed against the project decision criteria. The final package may include methods, formulation parameters, analytical data, functional results, control interpretation, identified limitations, and recommendations for repeat studies, scale transition, or carrier comparison.
Exosome delivery projects require expertise across RNA chemistry, extracellular vesicle preparation, analytical measurement, and cell biology. Our integrated approach is designed to reduce gaps between these disciplines and provide data that can support practical research decisions.
Exosome-mediated RNA delivery can support diverse discovery and platform-development programs. Application design should account for the RNA mechanism, recipient-cell model, required intracellular destination, and evidence needed to demonstrate functional transfer.
Whether your project involves siRNA knockdown, mRNA expression, miRNA modulation, circRNA research, guide RNA delivery, or comparison with another nanocarrier, our team can develop a workflow aligned with your RNA cargo and experimental model. Support is available for cargo review, vesicle sourcing, loading-method selection, purification, characterization, uptake testing, functional validation, stability evaluation, and research-scale process development. Contact us with your RNA specifications, available materials, target-cell model, and desired readouts to begin a technical assessment.
Exosomes are a subpopulation of extracellular vesicles, which are classified into exosomes, microvesicles, and apoptotic bodies.
Exosomes, as an emerging skincare ingredient, contain abundant bioactive molecules, including growth factors and lipids. Their application promotes skin regeneration and repair, improving texture and reducing wrinkles. Additionally, exosomes offer moisturizing, antioxidant, and anti-inflammatory effects, protecting the skin from environmental damage and maintaining its health and youthfulness.
Exosomes have diverse applications, ranging from biomedical research to regenerative medicine and drug delivery. In research, they serve as valuable tools for understanding intercellular communication and disease mechanisms. As natural nanocarriers, exosomes show promise in targeted drug delivery for various therapeutics, including cancer treatments and regenerative therapies. Additionally, exosomes hold potential in cosmetic and skincare products, where their ability to deliver bioactive molecules like growth factors and antioxidants can improve skin health and combat aging. With their versatility and biocompatibility, exosomes continue to be a focus of scientific investigation and innovation across multiple fields.
Exosomes and stem cells each offer unique advantages in regenerative medicine. Stem cells possess the ability to differentiate into various cell types, directly contributing to tissue repair and regeneration. However, exosomes, as extracellular vesicles secreted by cells, facilitate intercellular communication and modulate cellular functions. They are smaller, more stable, and less immunogenic than stem cells, making them potentially safer and easier to handle for targeted drug delivery. While stem cells provide direct cell replacement, exosomes offer a versatile and promising approach for promoting tissue repair, angiogenesis, and immune regulation. Therefore, the choice between exosomes and stem cells depends on the specific therapeutic goals and requirements of each application.
Extracellular vesicles (EVs) are lipid bilayer particles released by cells, ranging from 20-30 nanometers to over 10 micrometers. They cannot replicate and are classified into exosomes, microvesicles, and apoptotic bodies based on size and synthesis pathways. EVs contain proteins (such as adhesion molecules, cytoskeletal proteins, cytokines, ribosomal proteins, growth factors, and metabolic enzymes), lipids (such as cholesterol, lipid rafts, and sphingolipids), nucleic acids (such as DNA, mRNA, and miRNA), metabolites, and even organelles, participating in intercellular communication and regulating biological processes.
Loading ......
